UBS Downgrades US Stock Market Outlook
Investment bank UBS has downgraded its outlook on U.S. equities, warning clients of “asymmetric structural downside risks” to the dollar. The firm argues that key factors behind years of U.S. market outperformance, such as strong corporate buybacks and tech dominance, are beginning to erode.
For years, U.S. stocks have outpaced global markets, making up a staggering 66% of the world's total stock market capitalization with only 4% of its population and 26% of its economic output. This dominance was fueled by factors like strong earnings growth, a stable regulatory environment, and the U.S. dollar's status as the world's reserve currency. A central pillar of the downgrade is the U.S. dollar, which UBS warns faces "asymmetric structural downside risks." The bank forecasts the euro will strengthen against the dollar. Historically, a 10% drop in the dollar's trade-weighted index has led to U.S. equities underperforming foreign markets by about 4%. The power of corporate stock buybacks, another driver of U.S. market strength, is reportedly fading. While S&P 500 companies spent a near-record $1.2 trillion on repurchases in 2025, the buyback yield is now merely on par with global competitors, diminishing a key advantage for U.S. earnings-per-share growth. The market's performance has been heavily concentrated in a few technology giants. In the last quarter of 2025, technology and communication services sectors accounted for 66% of the S&P 500's total earnings-per-share growth. This reliance on a small number of "Magnificent Seven" companies creates volatility risks when their leadership falters. Valuations for U.S. stocks are also a concern, trading at a 35% premium compared to global peers, far above the average premium of 4% since 2010. This stretched valuation comes as earnings growth rates between U.S. and foreign companies are expected to become more evenly matched. UBS also points to an "uncertainty premium" driven by shifting White House policies. The bank highlights this year's changes in trade policy, proposed limits on credit card rates, and renewed pressure on drug pricing as factors creating headwinds for corporate earnings. In response to these risks, some institutional investors are shifting new allocations to overseas markets. Recent data shows a significant portion of capital flowing into regions outside the U.S., with 45% of recent fund flows going to non-U.S. equity markets. UBS has maintained an overweight position on emerging market equities.
